Brief: Nabriva Says Lefamulin Demonstrates Anti-Inflammatory Activity In Pre-Clinical Study
23/07/2020 12:23
July 23 (Reuters) - Nabriva Therapeutics PLC NBRV.O :
* NABRIVA THERAPEUTICS PLC - LEFAMULIN DEMONSTRATES
ANTI-INFLAMMATORY ACTIVITY IN PRE-CLINICAL STUDY
* NABRIVA - AWARDED GRANT FUNDING FROM AUSTRIAN RESEARCH
PROMOTION
AGENCY TO CHARACTERIZE ANTI-INFLAMMATORY, IMMUNOMODULATORY
PROPERTIES OF LEFAMULIN
Source text for Eikon: ID:nGNX3txjvN
Further company coverage: NBRV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nabriva Therapeutics
See all newsBrief: Nabriva Therapeutics And Units Enter Asset Purchase Agreement With Sumitomo Pharma
Brief: Nabriva Therapeutics Says Received Delisting Determination Letter From Nasdaq
Brief: Nabriva Therapeutics Receives Notice Of Delisting Or Failure To Satisfy Continued Listing Rule From Nasdaq
Brief: Nabriva Therapeutics - On Jan 31, Co's Unit Entered Into Letter Agreement With 2 Units Of Merck & Co, About Distribution Agreement, Dated July 15, 2020
Brief: Nabriva Therapeutics Provides Corporate Update